Resveratrol and SIRT1/AMPK pathways in age-related cognitive decline: a review
This review reports that resveratrol, especially in bioavailability-enhanced formulations, acts on SIRT1/AMPK-related pathways at human-achievable plasma levels; preclinical and clinical findings are summarized, but clinical results remain inconsistent. [1]
Automatic summary · not editorially reviewed
The key findings
The review describes resveratrol as a multi-target neuroprotective agent affecting several aging and neurodegeneration pathways at once. [1]
Preclinically, resveratrol is reported to augment BDNF-TrkB-CREB signaling and support hippocampal neurogenesis. [1]
In clinical research, resveratrol has been associated with enhanced cognitive function in certain trials, but findings remain inconsistent. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Middle-aged and elderly individuals and preclinical models discussed in a review of age-related cognitive decline
- Summary based on
- Study abstract
- Original publication
- October 1, 2026
Review scope: resveratrol pathways in cerebral aging
The review addresses age-related cognitive decline and neurodegenerative disorders, which it describes as major neuropsychiatric challenges because current therapies largely fail to address the complexities of cerebral aging. It presents resveratrol, a natural polyphenol, as a multi-target neuroprotective agent that can affect several pathways involved in aging and neurodegeneration at the same time. The authors state that the accumulated evidence supports starting extensive randomized controlled trials in middle-aged and elderly people.
Supporting source [1]
Preclinical mechanisms and human-achievable plasma levels
According to the review, resveratrol activates SIRT1, stimulates AMPK, inhibits mTORC1, restores autophagic flux and promotes mitochondrial biogenesis at plasma concentrations of 1–10 μmol/L that are achievable in humans, particularly with bioavailability-enhanced formulations. Preclinically, it is reported to augment BDNF-TrkB-CREB signaling, support hippocampal neurogenesis, reduce amyloid-β and tau pathology, and alleviate neuroinflammation and glial senescence. These are described as preclinical findings, not demonstrated human benefits.
Supporting source [1]
Clinical associations in trials remain inconsistent
In clinical research, the review states, resveratrol has been associated with enhanced cognitive function and hippocampal connectivity in certain trials, and with reduced inflammatory and metabolic markers linked to brain aging. The authors note that these findings remain inconsistent. The review calls resveratrol a potential multi-target agent for mitigating age-related cognitive decline, citing its safety record and improved pharmacokinetic properties, and argues for large randomized controlled trials in middle-aged and elderly individuals.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. Preclinical mechanism findings are not evidence of human cognitive benefit, and the clinical associations described are inconsistent.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Ahmed Salem Al-Dhahi, Hayder M. Al-Kuraishy, Mohamed N. Fawzy, Gaber El-Saber Batiha · doi.org · October 1, 2026